The US Payor Landscape： Results from a Survey of Medical Directors and Pharmacy Directors on Comparative-Effectiveness Research
The US Payor Landscape： Results from a Survey of Medical Directors and Pharmacy Directors on Comparative-Effectiveness Research作者机构：TPG National Payor Roundtable Glastonbury Connecticut 06033 USA The JeSTARx Group New Jersey 07435 USA The Pharmacy Group Glastonbury Connecticut 06033 USA SM Health Communications Valley Cottage New York 10989 USA The JeSTARx Group Dallas Texas 75219 USA
出 版 物：《Journal of Pharmacy and Pharmacology》 (药剂与药理学（英文版）)
年 卷 期：2014年第2卷第7期
页 面：432-438页
学科分类：1007[医学-药学(可授医学、理学学位)] 10[医学]
主 题：Payer survey P&T Committees comparative-effectiveness research managed care formularies.
摘 要：The paper is to determine the types of approaches preferred by medical and pharmacy directors of US payer organizations to enhance the Pharmacy ＆ Therapeutic decision-making process and how medications accepted onto the formulary should be covered. An online interactive survey of US medical and pharmacy directors was conducted in 2012. In addition to a 10-point Likert scale （10 = agree completely, 1 = disagree completely）, qualitative responses and interpretive analysis were used to explore beliefs about certain statements. The results showed that the 30 respondents （20 medical directors and 10 pharmacy directors） rated current progress in obtaining usable CER （comparative-effectiveness research） at only an average of 4.17 on the 10-point scale. They hoped to regularly utilize CER information in formulary decision making by 2015 （average rating, 6.03）. The rating of evidence-based medicine use in coverage decision making today was somewhat higher, at an average of 7.08 （medical directors, 7.38; pharmacy directors, 6.40）. The survey participants believe that emerging CER results will greatly affect the following areas： optimization/improvement of clinical guidelines, medical/pharmacy benefit management, assessments of the value and appropriateness of interventions, and pharmaceutical research and development. Therefore, payers expect CER to play an increasing role in helping them determine the value of new therapies.
维普期刊数据库